Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 1.00 |
| ▸ | PPARD | Q03181 | 9/20 | 1.00 |
| ▸ | PPARA | Q07869 | 8/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGAV | P06756 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14499752 | 0.94 | PPARG (0.89) | PPARGPPARDPPARAHRH3ITGB3 | |
| SCHEMBL5410702 | 0.85 | PPARG (1.00) | PPARGPPARDPPARA | |
| SCHEMBL14499753 | 0.85 | PPARG (1.00) | PPARGPPARDPPARAHRH3ITGB3 | |
| SCHEMBL5407564 | 0.81 | PPARG (1.00) | PPARGPPARDPPARA | |
| SCHEMBL5414131 | 0.79 | PPARG (1.00) | PPARGPPARDPPARA | |
| SCHEMBL6704879 | 0.75 | PPARG (0.71) | PPARGPPARDPPARA | |
| SCHEMBL5407899 | 0.74 | PPARG (1.00) | PPARGPPARDPPARA | |
| SCHEMBL6484840 | 0.74 | PPARG (0.65) | PPARGPPARDPPARA | |
| SCHEMBL5407544 | 0.73 | PPARG (1.00) | PPARGPPARDPPARA | |
| SCHEMBL5421507 | 0.73 | PPARG (1.00) | PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2007-06-21 | — | — | US | disclosed |
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2007-06-21 | — | — | US | disclosed |
| US-7192970-B2 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-03-20 | — | — | US | disclosed |
| US-7192970-B2 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | PPARG 2/4885PPARD 4/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.